Cheng AL, Kang YK, Chen Z et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25–34CrossRefPubMedGoogle Scholar

Hennenberg M, Trebicka J, Stark C et al. (2009) Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. Br J Pharmacol 157: 258–270CrossRefPubMedGoogle Scholar

Liu L, Cao Y, Chen C et al. (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851–11858CrossRefPubMedGoogle Scholar

Llovet JM, Ricci S, Mazzaferro V et al.; SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378–390CrossRefPubMedGoogle Scholar

Mejias M, Garcia-Pras E, Tiani C et al. (2009) Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 49: 1245–1256CrossRefPubMedGoogle Scholar